Two-year results from FISH&CHIPS, a real world, multi-center, retrospective clinical study with 90,553 patients conducted by the National Health Service (NHS) England were presented at the 2023 European Society of Cardiology (ESC) Congress meeting in Amsterdam by Principal Investigator, Dr. Tim Fairbairn, Consultant Cardiologist, Liverpool Heart and Chest Hospital. FFRCT (CCTA-derived Fractional Flow Reserve) is part of a clinical pathway for

The wait is finally over. Mid-Southerners can now use Methodist Le Bonheur Healthcare's new Healthier 901 fitness app to track their progress toward the Healthier 901 Challenge to lose one million pounds in three years. The free tool provides accountability for those participating in the challenge, along with numerous resources to support challenge participants, including articles about healthy living, pre-recorded workouts ranging from low-impact to high-intensity interval

NextGen Healthcare Inc., a leading provider of innovative, cloud-based healthcare technology solutions, and Luma Health, innovator of the market-leading Patient Success Platform™, announced an expanded alliance to equip ambulatory organizations nationwide with artificial intelligence (AI)-enhanced solutions for patient communications, beginning with intake and self-scheduling. NextGen® Patient Engage and NextGen® Self-Scheduling powered by Luma 

The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study (EFS), led by Principal Investigator Isaac George, MD. The first case was performed in an 84-year-old woman

CVS Health®  today announced that it has launched Cordavis, a wholly owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce biosimilar products (an FDA approved biologic medication that is highly similar to, and has no clinically meaningful differences from, a biologic medicine already approved by the FDA) for the U.S. pharmaceutical market. The Cordavis products will be FDA approved, high quality, and easy for patients to use and will help ens

Tivic Health® Systems, Inc., a commercial-phase health technology company that develops and commercializes bioelectronic medicine, announced today that its Board of Directors has declared a 1-for-100 reverse stock split of the company’s issued and outstanding shares of common stock. The reverse stock split will become effective on August 23, 2023 (the “Effective Date”) at 12:01 AM Eastern Time. The company’s common stock is expected to begin trading on a split-adju

Health Recovery Solutions has been awarded a national group purchasing agreement for Virtual Care with Premier, Inc. Effective Aug. 15, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for telehealth and RPM technologies. For sixteen consecutive years, Premier has been recognized as one of the World's Most Ethical Companies®. Premier is a leading healthcare improvement company, u

Secure Exchange Solutions (SES), a Centauri Health Solutions company, and a leader in cloud-based clinical data exchange, announces an expanded collaboration with CyncHealth, the leading health data utility (HDU) and designated health information exchange (HIE) serving Nebraska and Iowa.  Serving over 5 million lives across 1,135 facilities and growing rapidly, CyncHealth needed a solution that was both scalable and able to meet existing and future industry requirements.

Susan G. Komen®, the world's leading breast cancer organization, today announced it is continuing its partnership with Nature's Bounty®, a Nestlé Health Science brand and a leader in scientifically-backed vitamin and nutritional supplements. This partnership will help support Komen's mission to end breast cancer forever by aligning with a partner that is committed to funding research and care services for those impacted by breast cancer. In addition to bei

Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including Energy Based Devices, Injectables, Aesthetic and Digital Dentistry, Personal Care, and more, today announced that it expects to release its financial results for H1 2023, ended June 30, on W